Get the Stockscreener App
8.61
0.82%
0.07
Pre-market:
8.49
-0.12
-1.39%
Immunitybio Inc stock is traded at $8.61, with a volume of 55.05M.
It is up +0.82% in the last 24 hours and up +55.98% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$8.54
Open:
$8.05
24h Volume:
55.05M
Relative Volume:
2.01
Market Cap:
$8.48B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-8.8763
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+30.06%
1M Performance:
+55.98%
6M Performance:
+277.63%
1Y Performance:
+120.77%
1-Day Range:
$7.60
$8.945
1-Week Range:
$5.93
$8.945
52-Week Range:
$1.83
$8.945
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.61 | 8.41B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.27 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.38 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
847.26 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.37 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.48 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
Conditional Approval for ANKTIVA in BCG-Unresponsive Non-Muscle Invasive Bladder CancerImmunityBio - Oncodaily
European Approval Ignites Surge for ImmunityBio Shares - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio Wins EU Anktiva Nod As Investors Weigh Execution Risks - simplywall.st
ImmunityBio Stock Soars 42% After New Anktiva Approvals. Here’s What’s Driving the Rally - TIKR.com
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsi - PharmiWeb.com
ImmunityBio Stock Maintains Golden Cross Signal - Intellectia AI
ImmunityBio (NASDAQ:IBRX) Shares Gap DownShould You Sell? - MarketBeat
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average - Benzinga
Regulatory Challenges Impact ImmunityBio Shares - timothysykes.com
ImmunityBio, Accord Healthcare Collaborate to Expand Anktiva Access in Europe - marketscreener.com
ImmunityBio Partners with Accord Healthcare to Expand Anktiva Access - Intellectia AI
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA - FinancialContent
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries - Stocktwits
ImmunityBio partners with Accord Healthcare to expand ANKTIVA across Europe - Investing.com
ImmunityBio, Inc. announces the expansion of access to its innovative drug Anktiva® in the EU through a new distribution partnership, while officially establishing an Irish subsidiary to provide strategic support for the comprehensive promotion of its products in - Bitget
ImmunityBio inks deal for Anktiva access in Europe (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch - Yahoo Finance
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up - Finviz
ImmunityBio (IBRX) Stock Jumps as EU Clears ANKTIVA for Bladder Cancer - Blockonomi
ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS - Yahoo Finance
ImmunityBio (IBRX) Soars to New High on Anktiva Future Expansion - Insider Monkey
ImmunityBio’s EU Anktiva Nod Sparks Questions On Valuation And Momentum - Yahoo Finance
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? - Nasdaq
ImmunityBio (IBRX) Stock Jumps as ANKTIVA Becomes First Approved Bladder Cancer Immunotherapy in Europe - CoinCentral
ImmunityBio Soars Over 40% as European Commission Approves Bladder Cancer Drug Anktiva - NAI500
Institution Moves: Does ImmunityBio Inc have a sustainable dividendTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn
ImmunityBio's Short Interest Turns Bullish Ahead of EU Decision - Intellectia AI
European Commission authorizes ImmunityBio’s ANKTIVA for bladder cancer By Investing.com - Investing.com South Africa
ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change - Finviz
ImmunityBio (NASDAQ:IBRX) Trading 41.9% HigherWhat's Next? - MarketBeat
ImmunityBio Stock Soars After EU Grants Conditional Approval for Anktiva - Intellectia AI
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer - AOL.com
ImmunityBio (NASDAQ:IBRX) Hits New 52-Week HighShould You Buy? - MarketBeat
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer - The Motley Fool
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals - Stocktwits
Immunitybio stock hits 52-week high at $8.28 - Investing.com
Why ImmunityBio Stock Is Soaring Today - AOL.com
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries - BioSpace
ImmunityBio Shares Rise After EU Conditional Authorization for Anktiva With BCG - marketscreener.com
What's Behind The Jump In ImmunityBio Stock? - Benzinga
Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva - Tokenist
Why ImmunityBio Stock Is Quietly Breaking Out - TipRanks
ImmunityBio (IBRX) jumps ahead of oncology event - MSN
ImmunityBio Stock Gains 19% Over Conditional Marketing Authorization From EC For ANKTIVA - Nasdaq
ImmunityBio stock soars after EU authorization for bladder cancer therapy - Investing.com Nigeria
ImmunityBio stock soars after EU authorization for bladder cancer therapy By Investing.com - Investing.com Canada
European Commission authorizes ImmunityBio’s ANKTIVA for bladder cancer - Investing.com
ImmunityBio Says Anktiva With BCG Wins EU Conditional Authorization for Bladder Cancer - marketscreener.com
ImmunityBio Wins EU Nod for ANKTIVA Bladder Cancer Therapy - TipRanks
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):